PCI Biotech Holding ASA
PCI Biotech is a publicly listed Norwegian biotechnology company with a unique technology to improve localised treatment of cancer. The company has a focused and competent organisation localised at Lysaker just outside Oslo, Norway, with extensive collaboration with international experts and service providers. Clinical development of the lead product started in 2009 and has so far shown very promising results in localised treatment of head & neck cancer. The company has started a Phase II study in head & neck cancer, and is preparing for a phase I/II study in bile duct cancer to start by end of 1H 2013.